Webinar Technology

Discovering New Drugs for Disease: Advancing Imaging in the Well

This webinar is brought to you by the Science/AAAS Custom Publishing Office

Discovering New Drugs for Disease:  Advancing Imaging in the Well

Recorded 14 September 2011



Imaging is one of the key technologies that are enabling advances in well-based screening studies, and multilabeled detection using plate-reading technologies is the foundation of screening platforms for drug discovery. As lead generation seeks to become more targeted and more clinically relevant, we see trends at all levels of automation as well as a movement from classical high throughput screens using over-expressing cell lines, to the use of phenotypic cell lines, high content analysis, and miniaturization. In this webinar, the second in a series of three exploring imaging from cell to well to animal, our panelists will focus on the use of well-based imaging technology, now and in the future. They will consider the role of screening in providing unbiased, statistically relevant data and the challenges faced in data management and image analysis. They will also explore the developing trends in establishing collaborations with academia and outsourcing through external organizations and the benefits that these links bring to the advancement of disease research.

During the webinar, our panelists will:

  • Consider the application of new technologies in drug discovery
  • Discuss the challenges faced when using well-based imaging
  • Examine how academic-industry collaborations might drive discovery 

For related products/technologies go to: www.perkinelmer.com/imaging.

Speaker bios

David W. Andrews, Ph.D.

McMaster University
Hamilton, Ontario 

David W. Andrews obtained his Ph.D. in medical biophysics from the University of Toronto and completed his postdoctoral training in cell biology at University of California, San Francisco. He is now a professor in Biochemistry and Biomedical Sciences as well as in Biomedical Engineering. Dr. Andrews holds a Tier 1 Canada Research Chair in Membrane Biogenesis and is director of the McMaster Biophotonics Facility, which he founded. His research interests include the assembly of proteins into the endoplasmic reticulum membrane, the molecular mechanisms by which Bcl-2 family proteins regulate apoptosis, high content screening, the development of new fluorescence microscopes, and automated image analysis. Since publishing his first paper in automated image analysis more than 25 years ago, Dr. Andrews has published more than 90 research papers and holds four patents. He is currently a contributing member of the Faculty of 1000 (www.facultyof1000.com) and is on the editorial board of BMC Cell Biology. 

Jeremy Simpson, Ph.D.

University College Dublin
Dublin, Ireland 

Jeremy Simpson carried out his Ph.D. work in the laboratory of Mike Lord and Lynne Roberts at the University of Warwick in the United Kingdom, working on trafficking of protein toxins, in particular ricin, in mammalian cells. After postdoctoral work at the Scripps Research Institute in San Diego, he returned to the United Kingdom and spent some time at the Imperial Cancer Research Fund in London. In 1999, he was awarded a long term EMBO fellowship allowing him to move with his then supervisor, Rainer Pepperkok, to the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany. For over nine years he worked at EMBL developing and applying novel high throughput imaging approaches to study membrane traffic. In 2008, Dr. Simpson was appointed as professor of cell biology at University College Dublin, Ireland. His laboratory currently applies high throughput imaging technologies to study trafficking between the endoplasmic reticulum and Golgi complex, and the internalization pathways taken by synthetic nanoparticles on exposure to cells. He is a fellow of the UCD Conway Institute, chairs the UCD Imaging Steering Committee, and runs the new UCD Cell Screening Laboratory.

Sean Sanders, Ph.D.

Washington, DC

Dr. Sanders did his undergraduate training at the University of Cape Town, South Africa, and his Ph.D. at the University of Cambridge, UK, supported by the Wellcome Trust. Following postdoctoral training at the National Institutes of Health and Georgetown University, Dr. Sanders joined TranXenoGen, a startup biotechnology company in Massachusetts working on avian transgenics. Pursuing his parallel passion for writing and editing, Dr. Sanders joined BioTechniques as an editor, before joining Science/AAAS in 2006. Currently Dr. Sanders is the Senior Editor for Custom Publishing for the journal Science and Program Director for Outreach.

Sponsored by

Get webinar alerts

For more information on upcoming webinars, recorded sessions and more, sign up for webinar alerts.

Sign up here